Toripalimab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Toripalimab
- Toripalimab: From Nasopharyngeal Carcinoma (Oncology) to Mixed-Type Autoimmune Hemolytic Anemia
Toripalimab: From Nasopharyngeal Carcinoma (Oncology) to Mixed-Type Autoimmune Hemolytic Anemia
One-Sentence Summary
Toripalimab is an anti-PD-1 monoclonal antibody used in cancer immunotherapy; it is registered in Singapore, but the approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for mixed-type autoimmune hemolytic anemia, with 0 clinical trials and 0 publications supporting this direction. This is a model prediction only, and PD-1 blockade is more often reported to trigger autoimmune hemolysis than to treat it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the Singapore licence record. Public information indicates nasopharyngeal carcinoma (FDA approval, October 2023). |
| Predicted New Indication | Mixed-type autoimmune hemolytic anemia |
| TxGNN Prediction Score | 93.76% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled record. Toripalimab is a humanized antibody that blocks PD-1 from binding to its ligands PD-L1 and PD-L2 (IC50 about 3.0 nM). This releases the brake on T-cell activity against tumours.
The mechanistic rationale for autoimmune hemolytic anemia is weak. Enhancing immune activity would be expected to worsen autoimmune hemolysis rather than relieve it. Checkpoint inhibitors are themselves reported to cause immune-mediated hemolysis. The high TxGNN score therefore likely reflects network associations in the knowledge graph rather than a plausible therapeutic mechanism, and the prediction should be treated with caution.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17212P | LOQTORZI Concentrate for Solution for Infusion 240mg/6ml | Infusion, solution concentrate | Not stated in the licence record |
Safety Considerations
- Drug Interactions: The interaction search returned one pharmacology entry, which is the drug's own target (PD-1, PDCD1) rather than a drug-drug interaction. No clinically relevant interacting drugs were identified.
- Class concern: PD-1 inhibitors are associated with immune-related adverse events, including hemolysis and severe skin reactions, which makes use in autoimmune haematological disease potentially harmful.
Please refer to the package insert for further safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone, with no clinical trials or literature. The biological direction (immune activation in an autoimmune disease) is unfavourable and may be harmful.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA record
- Mechanism of action data from DrugBank
- Any preclinical or clinical evidence that PD-1 blockade benefits autoimmune hemolytic anemia
- A safety assessment of immune-mediated hemolysis risk with checkpoint inhibitors
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.